Study to Evaluate Pharmacokinetics, Safety, and Tolerability Ildong COL-144 Tablet in Korean Healthy Volunteers

NCT ID: NCT03937648

Last Updated: 2019-05-06

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 64 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-08-01
• Study Completion Date: 2019-12-31

Brief Summary

A Randomized, Double blind, Placebo-controlled, Single-dose, Dose-escalation Study to Evaluate Pharmacokinetics, Safety, and Tolerability with Oral Administration of Ildong COL-144 tablet in Korean Healthy Volunteers

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

COL-144 50mg

Group Type: EXPERIMENTAL

COL-144 50mg

Intervention Type: DRUG

COL-144 50mg

COL-144 100mg

Group Type: EXPERIMENTAL

COL-144 100mg

Intervention Type: DRUG

COL-144 100mg

COL-144 200mg

Group Type: EXPERIMENTAL

COL-144 200mg

Intervention Type: DRUG

COL-144 200mg

COL-144 400mg

Group Type: EXPERIMENTAL

COL-144 400mg

Intervention Type: DRUG

COL-144 400mg

Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo

Interventions

COL-144 50mg

COL-144 50mg

Intervention Type: DRUG

COL-144 100mg

COL-144 100mg

Intervention Type: DRUG

COL-144 200mg

COL-144 200mg

Intervention Type: DRUG

COL-144 400mg

COL-144 400mg

Intervention Type: DRUG

Placebo

Placebo

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. A healthy adult who is at least 19 years old and less than 50 years old at the time of the screening visit.

2. A person whose body mass index (BMI) is greater than 19 kg/m2 and less than 28 kg/m2 at the time of the screening visit.

3. A person who is medically confirmed to be clinically insignificant in terms of a physical or mental condition by an investigator through a physical examination during the screening period.

4. A person who has agreed to use a combination of effective contraceptive methods or medically appropriate contraceptive methods from the date of administration of the investigational product to the end of the clinical trial (date of test for final safety assessment).

5. A male or female who has agreed not to provide sperm or eggs.

6. A woman whose serum/urine human chorionic gonadotropin (hCG) test results were negative and who is not pregnant or breastfeeding.

7. A person who has voluntarily decided and provided written consent to participate in clinical trials and follow precautions for test subjects.

8. A person who can collect blood and urine during the clinical trial, including follow-up visits.

Exclusion Criteria

1. A person with a history of gastrointestinal disorders (ex. Crohn's disease, ulcerative colitis, etc.) or surgery (except for simple appendectomy or herniotomy) that may affect the absorption of the investigational product.

3. A person with genetically caused galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.

4. A person with a history of hypersensitivity or clinically significant hypersensitivity to drugs that contain Lasmiditan or ingredients in the same category or other drugs (aspirin and non-steroidal anti-inflammatory drugs, antibiotics, etc.).

5. A person who has a history of drug abuse or whose urine drug screening test result during the screening period came back positive for abusive drug use.

6. A person who has donated partial or full amount of blood within 60 days of the screening visit, who has given blood through apheresis within 30 days, or who has been transfused within 60 days.

7. A person who has been administered with the investigational product or a bioequivalence study drug in another clinical trial or a bioequivalence study within 180 days of the screening visit.

8. A person who has taken a prescription drug, OTC(over the counter drug), herbal medicine, or health-functional food within 14 days of the screening visit.

9. A person who has smoked excessively within 14 days of the screening visit or whose (> 10 cigarettes/day) urine nicotine test result during the screening period came back positive.

10. A person who drank excessively within 14 days of screening visit (> 21 units/week).

11. A person who shows the following results in the vitality sign test during the screening period.

Systolic blood pressure ≥ 140 (millimeter of mercury) mmHg or <90 mmHg Diastolic blood pressure ≥ 90 mmHg or <60 mmHg Pulse> 100 bpm or < 45 bpm

12. A person who shows the following in the diagnostic test during the screening period.

• Aspartate aminotransferase (AST) and aminotransferase (ALT) values exceed the upper limit of reference (UNL) by more than 1.5 times.
• Bilirubin total value exceeds the upper limit of reference (UNL) by more than 1.5 times.

13. A person who tested positive in a blood serum test (hepatitis B test, human immunodeficiency virus (HIV) test, hepatitis C test, syphilis test) during the screening period.

14. A person who showed QTc(Heart rate-corrected QT) > 450 ms or clinically significant abnormalities in a 12-electrode electrocardiogram during the screening period.

16. Any other person who is judged to be inadequate to perform the clinical trials by the investigator.

• Minimum Eligible Age: 19 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

IlDong Pharmaceutical Co Ltd

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

ID-LAS-101

Identifier Type: -

Identifier Source: org_study_id